EASL Clinical Practice Guidelines

Addendum

During the editing process of the guidelines additional information on two phase 3 RCT mentioned in Table 4 was reported.

  1. The study comparing brivanib vs. placebo in patients with advanced HCC failing or intolerant to sorafenib was reported not meeting the primary end-point survival. http://www.businesswire.com/portal/site/home/email/alert (Jan 2012).
  2. The study comparing linifanib vs. sorafenib in first-line was halted by the DSMC at the interim analysis. Abbott's LiGHT (Linifanib Study M10-963) Early Study Closure).